OR WAIT null SECS
October 27, 2020
The Phase III clinical trial of NVX-CoV2373 is expected to be fully enrolled in the UK and will begin in the US and Mexico by the end of November 2020.
October 23, 2020
Gilead’s antiviral drug Veklury is the first approved treatment in the US for COVID-19.
October 21, 2020
Subsequent guidance and manufacturing realities make portions of USP Chapters and significantly less relevant. The authors suggest formal chapter revisions.
October 20, 2020
Orgenesis has completed its previously announced acquisition of Koligo Therapeutics with the additional acquisition of Tissue Genesis’ cell isolation technology, Icellator.
The company was selected because of its nucleic acid platform which, when combined with virotherapy, has the potential to treat liver cancer by using a lipid nanoparticle delivery system.
October 15, 2020
Regeneron will distribute Inmazeb treatment doses over the course of six years to BARDA.
The approval comes after a Phase III trial that showed Keytruda reduced the risk of disease progression or death by 35%.
October 09, 2020
The partnership aims to provide a platform of hiPSC-based assays, drug discovery technologies, high-throughput screening, and high-content screening.
October 06, 2020
The study, entitled CV-NCOV-002, is being held in Peru and Panama and has enrolled 690 participants, including older adults ages 61 and above, and younger participants 18 to 60 years old.
October 01, 2020
The approval of Nucala (mepolizumab) for treating hypereosinophilic syndrome represents the first drug approved for this group of rare blood disorders in nearly 14 years.